(Q41143972)

27 September 2017

1 reference

title

Clinical pharmacokinetics and pharmacodynamics of finasteride (English)

1 reference

27 September 2017

1 reference

1 reference

J F Steiner

1

1 reference

27 September 2017

1 January 1996

1 reference

Clinical Pharmacokinetics

27 September 2017

1 reference

27 September 2017

30

1 reference

27 September 2017

1

1 reference

27 September 2017

16-27

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199630010-00002

27 September 2017

0 references

cites work

High-performance liquid chromatographic determination of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a 4-azasteroid, in human plasma from a phase I study

1 reference

12 December 2020

Effect of Finasteride, a 5α-Reductase Inhibitor on Prostate Tissue Androgens and Prostate-Specific Antigen*

1 reference

12 December 2020

Picogram determination of finasteride in human plasma and semen by high-performance liquid chromatography with atmospheric-pressure chemical-ionization tandem mass spectrometry

1 reference

12 December 2020

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans

1 reference

12 December 2020

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, i

1 reference

12 December 2020

High-performance liquid chromatographic method for the determination of finasteride in human plasma at therapeutic doses

1 reference

12 December 2020

Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial

1 reference

12 December 2020

Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans

1 reference

12 December 2020

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers

1 reference

12 December 2020

Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride.

1 reference

12 December 2020

Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

1 reference

12 December 2020

Management of drug therapy in the elderly

1 reference

12 December 2020

The clinical development of a 5α-reductase inhibitor, finasteride

1 reference

12 December 2020

Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients

1 reference

12 December 2020

Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men

1 reference

12 December 2020

Case report: finasteride-induced gynecomastia in a 62-year-old man

1 reference

12 December 2020

Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group

1 reference

12 December 2020

Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.

1 reference

12 December 2020

Androgen metabolism in men receiving finasteride before prostatectomy

1 reference

12 December 2020

Effect of finasteride on adrenal steroidogenesis in men

1 reference

12 December 2020

One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group

1 reference

12 December 2020

Potential activities of androgen metabolizing enzymes in human prostate

1 reference

12 December 2020

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men

1 reference

12 December 2020

The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

1 reference

12 December 2020

The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Finasteride, a steroid 5 alpha-reductase inhibitor, does not affect the oxidative metabolism of antipyrine

1 reference

12 December 2020

Finasteride: a 5 alpha-reductase inhibitor

1 reference

12 December 2020

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride: a slow-binding 5 alpha-reductase inhibitor.

1 reference

12 December 2020

Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men.

1 reference

12 December 2020

Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol

1 reference

12 December 2020

Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5α-reductase inhibitor

1 reference

12 December 2020

10.2165/00003088-199630010-00002

Identifiers

DOI

1 reference

PubMed ID

8846625

Dimensions Publication ID

27 September 2017

1012510585

0 references

Fatcat ID

release_k65uztaurzf3fcq37d74uuizqy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k65uztaurzf3fcq37d74uuizqy

24 November 2022

mapped directly with Wikidata item

PubMed ID

8846625

1 reference

PubMed ID

8846625